文献速递白血病造血干细胞移植与细胞治疗

复输CD19 CAR T细胞用于儿童急性淋巴细胞白血病复发预防与治疗

Reinfusion of CD19 CAR T cells for relapse prevention and treatment in children with acute lymphoblastic leukemia.
PubMed 文献 · Blood Adv · 2024-01-01

该回顾性研究分析了81次CAR T细胞复输(CARTr),涉及79例患儿,用于复发预防、微小残留病(MRD)/复发治疗或对首次CAR T细胞输注(CARTi)无反应者。复发预防组完全缓解(CR)率为52%(外周B细胞恢复组38%,骨髓原始细胞组78%),MRD/复发组CR率为50%,对CARTi无反应组为0/8。毒性一般较轻,仅MRD/复发治疗组出现≥3级细胞因子释放综合征(n=6)或神经毒性(n=1)。

要点

  • 复发预防性CARTr的CR率为52%,其中骨髓原始细胞组78%,外周B细胞恢复组38%。
  • MRD/复发治疗性CARTr的CR率为50%,对CARTi无反应者CR率为0/8。
  • CARTr毒性一般较轻,≥3级CRS或神经毒性仅见于MRD/复发治疗组。

核心结论

  • 复输CTL019/替沙基仑赛或huCART19是安全的,可能降低部分患者的复发风险,并可在CD19+复发中重新诱导缓解。

研究设计与样本

  • 回顾性综述,纳入3项临床试验或商业替沙基仑赛的鼠源(CTL019)或人源化(huCART19)抗CD19/4-1BB CAR T细胞复输。
  • 262次初次治疗中81次后续至少1次复输(研究性CTL019 n=44;huCART19 n=26;替沙基仑赛 n=11),代表79例患者。

主要发现

  • 63次复发预防性复输中52%达到CR(外周B细胞恢复组15/40 [38%];骨髓原始细胞组18/23 [78%])。
  • 外周B细胞恢复组中,淋巴细胞清除与CARTr应答相关(OR 33.57;P=0.015),骨髓原始细胞组不相关(OR 0.30;P=0.291)。
  • CARTr达CR者24个月累积复发率为29%,未应答者为61%(P=0.259)。
  • MRD/复发治疗性CARTr的CR率为50%(5/10),对CARTi无反应者为0/8。
  • 毒性一般较轻,仅MRD/复发治疗组观察到≥3级细胞因子释放综合征(n=6)或神经毒性(n=1)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Relapse after CD19-directed chimeric antigen receptor (CAR)-modified T cells remains a substantial challenge. Short CAR T-cell persistence contributes to relapse risk, necessitating novel approaches to prolong durability. CAR T-cell reinfusion (CARTr) represents a potential strategy to reduce the risk of or treat relapsed disease after initial CAR T-cell infusion (CARTi). We conducted a retrospective review of reinfusion of murine (CTL019) or humanized (huCART19) anti-CD19/4-1BB CAR T cells across 3 clinical trials or commercial tisagenlecleucel for relapse prevention (peripheral B-cell recovery [BCR] or marrow hematogones ≤6 months after CARTi), minimal residual disease (MRD) or relapse, or nonresponse to CARTi. The primary endpoint was complete response (CR) at day 28 after CARTr, defined as complete remission with B-cell aplasia. Of 262 primary treatments, 81 were followed by ≥1 reinfusion (investigational CTL019, n = 44; huCART19, n = 26; tisagenlecleucel, n = 11), representing 79 patients. Of 63 reinfusions for relapse prevention, 52% achieved CR (BCR, 15/40 [38%]; hematogones, 18/23 [78%]). Lymphodepletion was associated with response to CARTr for BCR (odds ratio [OR], 33.57; P = .015) but not hematogones (OR, 0.30; P = .291). The cumulative incidence of relapse was 29% at 24 months for CR vs 61% for nonresponse to CARTr (P = .259). For MRD/relapse, CR rate to CARTr was 50% (5/10), but 0/8 for nonresponse to CARTi. Toxicity was generally mild, with the only grade ≥3 cytokine release syndrome (n = 6) or neurotoxicity (n = 1) observed in MRD/relapse treatment. Reinfusion of CTL019/tisagenlecleucel or huCART19 is safe, may reduce relapse risk in a subset of patients, and can reinduce remission in CD19+ relapse.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Myers RM, Devine K, Li Y, et al. Reinfusion of CD19 CAR T cells for relapse prevention and treatment in children with acute lymphoblastic leukemia. Blood Adv. 2024. PMID: 38386999. doi:10.1182/bloodadvances.2024012885

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。